Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8233317 | International Journal of Radiation Oncology*Biology*Physics | 2010 | 9 Pages |
Abstract
Isolated RNF is a rare occurrence after breast-conserving therapy. Patients with the HER-2 (not treated with trastuzumab) and basal subtypes appear to be at higher risk of developing RNF although this risk is not high enough to justify the addition of RNI. Low rates of RNF in patients with one to three positive nodes suggest that tangential RT without RNI is reasonable in most patients.
Keywords
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Jennifer Y. M.D., Alphonse G. M.D., Ph.D., Paul L. M.D., Rita Abi M.D., Meera B.A., Jennifer R. M.D., Julia S. M.D., Michele A. M.D., Barbara L. M.D., Ph.D., Jay R. M.D.,